Health systems can proactively reduce the number of CKD patients who “fall off” the ledge and require dialysis or transplant.
KidneyIntelXTM, our laboratory-developed test (LDT), has been validated in two large cohorts to be a highly-reliable, bioprognosticTM methodology, that yields a simple-to-understand, custom risk score, predicting which adult patients with type 2 diabetes and with chronic kidney disease stages 1-3 are at low, intermediate or high risk for rapid progressive decline in kidney function.
When your clinicians combine information gathered through KidneyIntelX with newer cardio- and reno-protective therapies, it’s a win-win. They will know which patients are at higher to lower risk for rapid disease progression, and therefore, can appropriately target resources and medications shown to be more effective at slowing or preempting disease progression and advancing kidney health.
Here’s how our 3-part, proprietary methodology – bioprognosisTM for kidney health – works: